SEC FILINGS


Form 10-K
ACADIA PHARMACEUTICALS INC filed this Form 10-K on 02/27/2019
Document Outline
Entire Document (9384.6 KB)
Subdocument 1 - 10-K - 10-K
Page 1 - UNITED STATES
Page 2 - ACADIA PHARMACEUTICALS INC.
Page 3 - PART I
Page 4 - www.acadia-pharm.com
Page 5 - N/A
Page 6 - Our Pipeline
Page 7 - Pimavanserin as a Treatment for Dementia-Related Psychosis
Page 8 - p=0.0018
Page 9 - Pimavanserin as an Adjunctive Treatment for Schizophrenia
Page 10 - Trofinetide
Page 11 - Intellectual Property
Page 12 - Collaboration Agreements
Page 13 - N/A
Page 14 - Coverage and Reimbursement
Page 15 - Healthcare Reform
Page 16 - N/A
Page 17 - Manufacturing and Distribution
Page 18 - Sales and Marketing
Page 19 - You should consider carefully the following information about the risks described below, together wi
Page 20 - If we do not obtain regulatory approval of NUPLAZID for other indications in the United States, or f
Page 21 - NUPLAZID has only been studied in a limited number of patients and in limited populations. As we con
Page 22 - We currently have limited experience as a company in marketing and distributing pharmaceutical produ
Page 23 - Our ability to generate product revenues will be diminished if NUPLAZID does not receive coverage fr
Page 24 - Healthcare reform measures may negatively impact our ability to sell NUPLAZID or our product candida
Page 25 - N/A
Page 26 - We are subject, directly and indirectly, to federal, state and foreign healthcare laws and regulatio
Page 27 - If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Progr
Page 28 - The FDA granted marketing approval of NUPLAZID for the treatment of hallucinations and delusions ass
Page 29 - If we fail to obtain the capital necessary to fund our operations, we will be unable to successfully
Page 30 - Changes in funding for the FDA and other government agencies could hinder their ability to hire and
Page 31 - We do not have a partner for the development of pimavanserin, and are solely responsible for the adv
Page 32 - Delays, suspensions and terminations in our clinical trials could result in increased costs to us an
Page 33 - If conflicts arise with our collaborators, they may act in their self-interests, which may be advers
Page 34 - Even if we or our collaborators successfully complete the clinical trials of product candidates, the
Page 35 - If we are unable to attract, retain, and motivate key management, research and development, and sale
Page 36 - We have recently increased the size of our organization, and will need to continue to increase the s
Page 37 - If we fail to comply with the obligations in agreements under which we license intellectual property
Page 38 - U.S. federal income tax reform could adversely affect our business and financial condition.
Page 39 - We may not be able to continue or fully exploit our collaborations with outside scientific and clini
Page 40 - Risks Related to Our Intellectual Property
Page 41 - Confidentiality agreements with employees and others may not adequately prevent disclosure of our tr
Page 42 - The patent applications of pharmaceutical and biotechnology companies involve highly complex legal a
Page 43 - Risks Related to Our Industry
Page 44 - If product liability lawsuits are brought against us, we may incur substantial liabilities and may b
Page 45 - We are dependent on information technology systems, infrastructure and data, which exposes us to dat
Page 46 - Risks Related to Our Common Stock
Page 47 - If we or our stockholders sell substantial amounts of our common stock, the market price of our comm
Page 48 - Adverse securities and credit market conditions may significantly affect our ability to raise capita
Page 49 - N/A
Page 50 - PART II
Page 51 - Statement of Operations
Page 52 - Overview
Page 53 - Financial Operations Overview
Page 54 - Selling, General and Administrative Expenses
Page 55 - Critical Accounting Policies and Estimates
Page 56 - Chargebacks
Page 57 - Comparison of the Years Ended December 31, 2018 and 2017
Page 58 - Comparison of the Years Ended December 31, 2017 and 2016
Page 59 - Liquidity and Capital Resources
Page 60 - Contractual Obligations
Page 61 - Off-Balance Sheet Arrangements
Page 62 - Changes in Internal Control Over Financial Reporting
Page 63 - Report of Independent Registered Public Accounting Firm
Page 64 - N/A
Page 65 - PART III
Page 66 - PART IV
Page 67 - N/A
Page 68 - N/A
Page 69 - SIGNATURES
Page 70 - Report of Independent Registered Public Accounting Firm
Page 71 - ACADIA PHARMACEUTICALS INC.
Page 72 - ACADIA PHARMACEUTICALS INC.
Page 73 - ACADIA PHARMACEUTICALS INC.
Page 74 - ACADIA PHARMACEUTICALS INC.
Page 75 - ACADIA PHARMACEUTICALS INC.
Page 76 - ACADIA PHARMACEUTICALS INC.
Page 77 - ACADIA PHARMACEUTICALS INC.
Page 78 - ACADIA PHARMACEUTICALS INC.
Page 79 - ACADIA PHARMACEUTICALS INC.
Page 80 - ACADIA PHARMACEUTICALS INC.
Page 81 - ACADIA PHARMACEUTICALS INC.
Page 82 - ACADIA PHARMACEUTICALS INC.
Page 83 - ACADIA PHARMACEUTICALS INC.
Page 84 - ACADIA PHARMACEUTICALS INC.
Page 85 - ACADIA PHARMACEUTICALS INC.
Page 86 - ACADIA PHARMACEUTICALS INC.
Page 87 - ACADIA PHARMACEUTICALS INC.
Page 88 - ACADIA PHARMACEUTICALS INC.
Page 89 - ACADIA PHARMACEUTICALS INC.
Page 90 - ACADIA PHARMACEUTICALS INC.
Page 91 - ACADIA PHARMACEUTICALS INC.
Page 92 - ACADIA PHARMACEUTICALS INC.
Page 93 - ACADIA PHARMACEUTICALS INC.
Page 94 - SCHEDULE II Valuation and Qualifying Accounts
Subdocument 2 - EX-4..2 - EX-4..2
Page 1 - Exhibit 4.2
Page 2 - Exhibit 4.2
Page 3 - Exhibit 4.2
Page 4 - Exhibit 4.2
Page 5 - Exhibit 4.2
Page 6 - Exhibit 4.2
Page 7 - Exhibit 4.2
Page 8 - Exhibit 4.2
Page 9 - Exhibit 4.2
Page 10 - Exhibit 4.2
Subdocument 3 - EX-10..26 - EX-10..26
Page 1 - Exhibit 10.26
Page 2 - TABLE OF CONTENTS
Page 3 - Licence Agreement Page ii
Page 4 - FEE schedule49
Page 5 - THIS LICENCE AGREEMENT
Page 6 - Commercialization Plan
Page 7 - Development Milestone Fees
Page 8 - Licence Agreement Page 4
Page 9 - Licence Agreement Page 5
Page 10 - Combination Products
Page 11 - Patents
Page 12 - Licence Agreement Page 8
Page 13 - Term
Page 14 - Bankruptcy Code
Page 15 - Licence Agreement Page 11
Page 16 - Licence Agreement Page 12
Page 17 - Licence Agreement Page 13
Page 18 - Licence Agreement Page 14
Page 19 - Licence Agreement Page 15
Page 20 - Alliance Manager
Page 21 - Licence Agreement Page 17
Page 22 - Licence Agreement Page 18
Page 23 - Licence Agreement Page 19
Page 24 - Licence Agreement Page 20
Page 25 - Licence Agreement Page 21
Page 26 - Licence Agreement Page 22
Page 27 - Licence Agreement Page 23
Page 28 - Licence Agreement Page 24
Page 29 - Licence Agreement Page 25
Page 30 - Licence Agreement Page 26
Page 31 - Licence Agreement Page 27
Page 32 - Licence Agreement Page 28
Page 33 - Licence Agreement Page 29
Page 34 - Licence Agreement Page 30
Page 35 - Licence Agreement Page 31
Page 36 - Licence Agreement Page 32
Page 37 - Licence Agreement Page 33
Page 38 - Joint Improvement
Page 39 - Licence Agreement Page 35
Page 40 - Licence Agreement Page 36
Page 41 - Licence Agreement Page 37
Page 42 - provided
Page 43 - Defaulting Party
Page 44 - Licence Agreement Page 40
Page 45 - 21.1ACADIA and Neuren liability
Page 46 - ACADIA Indemnified Parties
Page 47 - Licence Agreement Page 43
Page 48 - Licence Agreement Page 44
Page 49 - DisputeDisputant
Page 50 - Licence Agreement Page 46
Page 51 - RelevantDocument
Page 52 - Licence Agreement Page 48
Page 53 - FEE schedule
Page 54 - Licence Agreement Page 50
Page 55 - Licence Agreement Page 51
Page 56 - SCHEDULE OF PATENTS AND PATENT APPLICATIONS
Page 57 - Exhibit a
Page 58 - EXECUTEDAGREEMENT
Subdocument 4 - EX-10..27 - EX-10..27
Page 1 - Exhibit 10.27
Page 2 - N/A
Page 3 - *** Confidential Treatment Requested
Page 4 - *** Confidential Treatment Requested
Page 5 - N/A
Page 6 - ARTICLE 1
Page 7 - ARTICLE 1
Page 8 - Project Common Areas
Page 9 - Procedure for Refusal OfferFirst Refusal Noticebona-fide third-party offer
Page 10 - First Refusal Space RentFirst Refusal Space Lease
Page 11 - Sublease PremisesExhibit I
Page 12 - Section 2.2.4Section 2.2.4
Page 13 - Briefs
Page 14 - Section 2.2.4.3
Page 15 - Section 3.2
Page 16 - LEED
Page 17 - Exhibit H
Page 18 - Controllable Expenses
Page 19 - Section 29.16Article 24
Page 20 - Section 4.5
Page 21 - Statement
Page 22 - Taxes and Other Charges for Which Tenant Is Directly Responsible
Page 23 - Accountant
Page 24 - CC RsExhibit F
Page 25 - Exhibit B
Page 26 - Article 10Section 6.4
Page 27 - LANDLORD'S FAILURE TO RESPOND TO THIS NOTICE WITHIN TEN (10) DAYS SHALL RESULT IN LANDLORD'S DEEMED
Page 28 - Payment for Improvements
Page 29 - ARTICLE 9
Page 30 - Section 10.1Section 10.1Section 10.1
Page 31 - Original Improvements
Page 32 - Section 10.3.2.4
Page 33 - Landlord Repair Notice
Page 34 - Damage Termination NoticeDamage Termination DateLandlord's Repair Estimate Notice
Page 35 - ARTICLE 13
Page 36 - Subject SpaceExhibit E
Page 37 - Section 14.2Section 14.4Section 14.1Section 14.2Article 14Section 14.4Section 14.2Article 14
Page 38 - Section 14.4Article 14
Page 39 - Permitted TransfereeNet Worth Permitted Transferee AssigneeControl
Page 40 - Sections 29.3229.33
Page 41 - Holdover Damages
Page 42 - ARTICLE 19
Page 43 - rent
Page 44 - Efforts to Relet
Page 45 - Bankruptcy CodeTolling DepositL C Draw EventL C FDIC Replacement Notice
Page 46 - L-C Amount; Maintenance of L-C by Tenant; Liquidated Damages
Page 47 - Section 19.1.3Article 21Article 21
Page 48 - Non-Interference By Tenant
Page 49 - ARTICLE 23
Page 50 - Termination of Right to Tenant's Signage
Page 51 - ADAApplicable Laws
Page 52 - Section 26.1Article 10Section 26.2
Page 53 - Article 28
Page 54 - Prohibition Against Recording or Publication
Page 55 - Article 16
Page 56 - Joint and Several
Page 57 - Counterparts
Page 58 - Section 10.1Article 10
Page 59 - Section 29.32
Page 60 - Compliance with Environmental LawsPermitted Chemicals
Page 61 - Development of the Project
Page 62 - Water SensorsWater SensorsSensor Areas
Page 63 - Section 29.39
Page 64 - Patriot Act
Page 65 - NOTE:
Page 66 - EXHIBIT A-1
Page 67 - EXHIBIT A-2
Page 68 - EXHIBIT A-3
Page 69 - EXHIBIT B
Page 70 - SECTION 2
Page 71 - Code
Page 72 - N/A
Page 73 - Over-Allowance AmountOver-Allowance PaymentsChange-Order
Page 74 - N/A
Page 75 - *** Confidential Treatment Requested
Page 76 - SCHEDULE 1
Page 77 - SCHEDULE 2
Page 78 - Deflections/Serviceability
Page 79 - Exterior Terraces
Page 80 - Electrical Service and Distribution Systems
Page 81 - Emergency Power
Page 82 - HVAC and Mechanical Equipment
Page 83 - LG Touch Screen Central Controller (AC Smart Premium)
Page 84 - SCHEDULE 3
Page 85 - EXHIBIT C
Page 86 - N/A
Page 87 - EXHIBIT D
Page 88 - N/A
Page 89 - N/A
Page 90 - N/A
Page 91 - EXHIBIT E
Page 92 - N/A
Page 93 - EXHIBIT F
Page 94 - N/A
Page 95 - SIGNATURE PAGE OF RECOGNITION OF
Page 96 - EXHIBIT G
Page 97 - N/A
Page 98 - N/A
Page 99 - N/A
Page 100 - N/A
Page 101 - EXHIBIT A
Page 102 - EXHIBIT B
Page 103 - SIGNATURE AUTHENTICATED
Page 104 - EXHIBIT H
Page 105 - USE OF NET EQUIVALENT LEASE RATES FOR COMPARABLE TRANSACTIONS
Page 106 - EXHIBIT I
Page 107 - with copies to
Page 108 - And, for sustainability-related notices only
Page 109 - N/A
Page 110 - N/A
Page 111 - OFFICE LEASE
Page 112 - TABLE OF CONTENTS
Page 113 - EXHIBIT
Page 114 - INDEX
Page 115 - Page(s)
Page 116 - Page(s)
Subdocument 5 - EX-21..1 - EX-21..1
Page 1 - N/A
Subdocument 6 - EX-23..1 - EX-23..1
Page 1 - N/A
Subdocument 7 - EX-31.1 - EX-31.1
Page 1 - N/A
Subdocument 8 - EX-32.1 - EX-32.1
Page 1 - N/A
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE (What's this?)
XBRL Viewer